UBS raises Marriott stock price target on Q1 results, RevPAR outlook

UBS raised its price target on Marriott International to $412 from $336 while keeping a Neutral rating, citing first-quarter results and an improved RevPAR outlook. Marriott also declared a quarterly dividend of $0.73 per share and announced routine governance updates at its annual meeting. The stock trades at $406.26, near UBS’s new target, and at 26.32x EV/EBITDA versus UBS’s 17-19x target range.

Analysis

The read-through is less about Marriott re-rating and more about the market conceding that asset-light lodging can stay expensive when earnings visibility improves. The important second-order effect is competitive: if Hilton is still preferred on unit growth while Marriott trades at a premium multiple, the market is effectively paying up for quality without getting the faster capacity expansion that usually justifies it. That makes MAR more vulnerable to even modest estimate misses than the headline target suggests, because the stock is already priced near the new fair-value corridor.

The bigger risk over the next 1-3 quarters is that RevPAR optimism becomes self-limiting: a softer consumer or tighter corporate travel budgets can flatten rate growth quickly, while elevated expectations make the downside asymmetric. In lodging, valuation compressions tend to happen faster than fundamental downgrades; a 5-10% cut to forward EBITDA can translate into a disproportionate 15-20% equity drawdown when the multiple is already stretched. The dividend and governance optics are supportive, but they do little to offset a crowded long/neutral positioning setup if macro travel data rolls over.

Contrarian take: the market may be underestimating how much of the bullish narrative is already embedded in the move from 15-17x to 17-19x EV/EBITDA. If Marriott merely sustains current performance rather than accelerating, upside is likely capped, while downside is amplified by the fact that the stock is trading above the implied range. The cleaner expression is not a bearish outright short on a high-quality compounder, but a relative-value trade against the operator with the weaker growth narrative and more room for multiple expansion if demand stays firm.

Key Decisions for Investors

• Do not chase MAR here; fade strength with a 1-3 month time horizon via a starter short only on rallies above current levels, using a tight stop if upside surprise in summer booking data keeps RevPAR revisions moving higher.
• Prefer a pair trade: long HLT / short MAR for 3-6 months. Thesis: HLT keeps the superior unit-growth premium while MAR is already priced for near-perfect execution; target 8-12% relative outperformance if lodging multiples normalize.
• If holding MAR, monetize via covered calls 1-2 quarters out to harvest elevated implied volatility; this is a good way to cap upside in a stock already near implied fair value.
• For event-driven traders, wait for the next quarterly update or monthly travel data before adding exposure; any 2-3 point RevPAR disappointment could create a fast 10-15% downside re-rate in MAR.
• Avoid adding long exposure until EV/EBITDA compresses back toward the high-teens range on a market selloff; risk/reward is materially better on pullbacks than at current levels.